Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mRECIST for HCC: Performance and novel refinements
Josep M. Llovet, Riccardo Lencioni
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 288-306
Open Access | Times Cited: 470

Showing 26-50 of 470 citing articles:

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
Wei‐Feng Qu, Zhen‐Bin Ding, Xu-Dong Qu, et al.
BJS Open (2022) Vol. 6, Iss. 5
Open Access | Times Cited: 41
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
Yizhen Fu, Wei Peng, Weixiang Zhang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 4, pp. 413-424
Closed Access | Times Cited: 41
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 34
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
Magdalena Espinoza, Maishara Muquith, Mir Lim, et al.
Gastroenterology (2023) Vol. 165, Iss. 1, pp. 286-288.e4
Closed Access | Times Cited: 33
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
Weihao Zhang, Kai Zhang, Changfu Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
Sarah Cappuyns, Gino Philips, Vincent Vandecaveye, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3650-3658
Open Access | Times Cited: 25
Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Zhiyuan Bo, Bo Chen, Zhengxiao Zhao, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 9, pp. 1730-1740
Open Access | Times Cited: 24
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma
Peiyi Xie, Mincheng Yu, Bo Zhang, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 1, pp. 93-107
Closed Access | Times Cited: 15
Comprehensive molecular classification predicted microenvironment profiles and therapy response for HCC
Yihong Chen, Xiangying Deng, Yin Li, et al.
Hepatology (2024) Vol. 80, Iss. 3, pp. 536-551
Open Access | Times Cited: 10
Use of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Combined With Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19‐9 in Predicting Colorectal Cancer Liver Metastasis
Hongbo Ji, Bo Qian, Jianjun Hu, et al.
Journal of Clinical Ultrasound (2025)
Open Access | Times Cited: 1
Added Value of Dynamic Contrast-Enhanced Ultrasound Analysis for Differential Diagnosis of Small (≤20 mm) Solid Pancreatic Lesions
Xiu-Yun Lu, Jiaying Cao, Sheng Chen, et al.
Ultrasound in Medicine & Biology (2025)
Closed Access | Times Cited: 1
Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
Margot T.M. Reinders, Maarten L. J. Smits, Karel van Erpecum, et al.
EJNMMI Research (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response
Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1034-1034
Open Access | Times Cited: 1
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Vinita Akula, Lily Chen, Yusuf Açıkgöz, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma
Riccardo Muglia, Massimo De Giorgio, Paolo Marra, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Closed Access | Times Cited: 1
Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma
Karim J. Halazun, Russell Rosenblatt, Neil Mehta, et al.
JAMA Surgery (2021) Vol. 156, Iss. 6, pp. 559-559
Open Access | Times Cited: 53
Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Jie Mei, Shaohua Li, QiJiong Li, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 167-176
Open Access | Times Cited: 48
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
Riad Salem, Daneng Li, Nicolas Sommer, et al.
Cancer Medicine (2021) Vol. 10, Iss. 16, pp. 5437-5447
Open Access | Times Cited: 46
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
Fei Yang, Guili Xu, Jintao Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
Bo Sun, Lijie Zhang, Tao Sun, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 30
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study
Masatoshi Kudo, Richard S. Finn, Shukui Qin, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 133-141
Open Access | Times Cited: 30
Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study
Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma
Zhongqi Sun, Zhongxing Shi, Yanjie Xin, et al.
Academic Radiology (2023) Vol. 30, pp. S81-S91
Open Access | Times Cited: 19

Scroll to top